OHSU

IRB #

IRB00009657

Title

NP28761: A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated with Crizotinib

Principal Investigator

Jeremy Cetnar

Study Purpose

The purpose of this study is to find out what effects, good or bad, RO5424802 (the study drug) has on you and your non-small cell lung cancer (NSCLC).

Medical Condition(s)

NSCLC

Eligibility Criteria

1. Male or female age 18 years or older
2. Confirmed locally advanced or metastatic NSCLC
3. ALK-rearrangement confirmed by an FDA-approved test
4. Must have received and failed at least one line of platinum-based chemotherapy and crizotinib
5. Tumor tissue available to check for ALK-rearrangement
6. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

F. Hoffmann-La Roche, Ltd.

Recruitment End

09/30/2014

Compensation Provided

No


Go Back